PharmaShots | Incisive News in 3 Shots

Subscribe Now

Denali Therapeutics

Denali Therapeutics Presented Results from P-I/II Clinical Trial for DNL310 in Children to Treat MPS II (Hunter Syndrome) at SSIEM 2023

Denali Therapeutics Presented Results from P-I/II Clinical Trial for DNL310 in Children to Treat MPS II (Hunter Syndrome) at SSIEM...

August 31, 2023

Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease

Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease

June 1, 2022

Denali Therapeutics Reports the Initiation of P-I/II Clinical Trial of DNL593 (PTV:PGRN) for the Treatment of Frontotemporal Dementia-Granulin

Denali Therapeutics Reports the Initiation of P-I/II Clinical Trial of DNL593 (PTV:PGRN) for the Treatment of Frontotemporal Demen...

March 10, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us